Dr. Hwang serves as Senior Vice President, Head of Clinical Research for Vir Biotechnology, where he is responsible for the Company’s clinical development portfolio. Since joining Vir in January 2021, Dr. Hwang has primarily overseen the development of the Company’s lead hepatitis B and delta candidates, elebsiran and tobevibart, as well as its HIV vaccine candidates, VIR-1111 and VIR-1388.
Dr. Hwang has focused his career on the study and development of treatments for serious infectious diseases, including HIV, hepatitis B, and hepatitis C, and hepatitis delta. His industry career began at Bristol-Myers Squibb, conducting exploratory clinical and translational research focused on early phase clinical development of HIV and hepatitis C treatments. He joined Merck & Co. in 2016, where he served as Executive Director and Product Development Lead in Global Clinical Development – Infectious Diseases and led the worldwide development and global approval of two treatments for HIV.
Dr. Hwang received his bachelor’s degree in molecular biology from Princeton University and his MD, PhD from West Virginia University with a dissertation focused on retroviral recombination. He completed his internal medicine residency and infectious disease fellowship at Vanderbilt University with research focused on the latent reservoir of HIV.
